Immunomodulation and Therapeutic Effects of a Monotherapy with Interleukin-2 as an Induction Therapy in Patients with Poor-Prognosis Acute Myeloid Leukemia

Haematology and Blood Transfusion / Hämatologie und Bluttransfusion - Acute Leukemias VII ◽

10.1007/978-3-642-71960-8_135 ◽

1998 ◽

pp. 967-977

Author(s):

D. L. Voliotis ◽

S. Schmitz ◽

P. Staib ◽

H. Tesch ◽

V. Diehl

Keyword(s):

Acute Myeloid Leukemia ◽

Induction Therapy ◽

Myeloid Leukemia ◽

Poor Prognosis ◽

Interleukin 2 ◽

Therapeutic Effects ◽

Patients With Poor Prognosis ◽

Download Full-text

Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia

Annals of Oncology ◽

10.1093/annonc/mdm451 ◽

2008 ◽

Vol 19 (1) ◽

pp. 128-134 ◽

Author(s):

L. Fianchi ◽

L. Pagano ◽

F. Leoni ◽

S. Storti ◽

M.T. Voso ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Elderly Patients ◽

Myeloid Leukemia ◽

Poor Prognosis ◽

Gemtuzumab Ozogamicin ◽

Patients With Poor Prognosis ◽

Download Full-text

Prognostic Relevance of Cytokine Receptor Expression in Acute Myeloid Leukemia: Interleukin-2 Receptor α-Chain (CD25) Expression Predicts a Poor Prognosis

PLoS ONE ◽

10.1371/journal.pone.0128998 ◽

2015 ◽

Vol 10 (9) ◽

pp. e0128998 ◽

Author(s):

Kazunori Nakase ◽

Kenkichi Kita ◽

Taiichi Kyo ◽

Takanori Ueda ◽

Isao Tanaka ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Poor Prognosis ◽

Interleukin 2 ◽

Receptor Expression ◽

Cytokine Receptor ◽

Cd25 Expression ◽

Interleukin 2 Receptor ◽

Prognostic Relevance ◽

Download Full-text

The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

Leukemia Research ◽

10.1016/j.leukres.2005.10.024 ◽

2006 ◽

Vol 30 (7) ◽

pp. 801-811 ◽

Author(s):

Francis J. Giles ◽

William T. Bellamy ◽

Zeev Estrov ◽

Susan M. O’Brien ◽

Srdan Verstovsek ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Elderly Patients ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Poor Prognosis ◽

Patients With Poor Prognosis ◽

Download Full-text

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients with Poor-prognosis Acute Myeloid Leukemia

Leukemia & Lymphoma ◽

10.1080/1042819021000016078 ◽

2002 ◽

Vol 43 (10) ◽

pp. 1951-1955 ◽

Author(s):

G.J. Roboz ◽

M.A. Knovich ◽

R.L. Bayer ◽

M.W. Schuster ◽

K. Seiter ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Poor Prognosis ◽

Gemtuzumab Ozogamicin ◽

Efficacy And Safety ◽

Patients With Poor Prognosis ◽

Download Full-text

High serum levels of soluble interleukin-2 receptor in acute myeloid leukemia: Correlation with poor prognosis and CD4 expression on blast cells

Cancer Epidemiology ◽

10.1016/j.canep.2012.03.011 ◽

2012 ◽

Vol 36 (5) ◽

pp. e306-e309 ◽

Author(s):

Kazunori Nakase ◽

Kenkichi Kita ◽

Taiichi Kyo ◽

Kota Tsuji ◽

Naoyuki Katayama

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Poor Prognosis ◽

Interleukin 2 ◽

Serum Levels ◽

Interleukin 2 Receptor ◽

Blast Cells ◽

Soluble Interleukin 2 Receptor ◽

Download Full-text

Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete Remission

Biology of Blood and Marrow Transplantation ◽

10.1016/j.bbmt.2019.09.025 ◽

2020 ◽

Vol 26 (3) ◽

pp. 463-471 ◽

Author(s):

Takaaki Konuma ◽

Tadakazu Kondo ◽

Shohei Mizuno ◽

Noriko Doki ◽

Jun Aoki ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Complete Remission ◽

Cell Transplantation ◽

Myeloid Leukemia ◽

Poor Prognosis ◽

Hematopoietic Cell Transplantation ◽

Conditioning Intensity ◽

First Complete Remission ◽

Patients With Poor Prognosis ◽

Download Full-text

Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial

Blood Cancer Journal ◽

10.1038/bcj.2017.50 ◽

2017 ◽

Vol 7 (6) ◽

pp. e568-e568 ◽

Author(s):

M Hunault-Berger ◽

◽

N Maillard ◽

C Himberlin ◽

C Recher ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Maintenance Therapy ◽

Phase Ii ◽

Myeloid Leukemia ◽

Poor Prognosis ◽

Patients With Poor Prognosis ◽

Download Full-text

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

Case Medical Research ◽

10.31525/ct1-nct03839771 ◽

2000 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

Maintenance Therapy ◽

Induction Therapy ◽

Myeloid Leukemia ◽

Intensive Chemotherapy ◽

Consolidation Therapy ◽

Newly Diagnosed ◽

Idh2 Mutation ◽

Download Full-text

Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy

Case Medical Research ◽

10.31525/ct1-nct03839446 ◽

2000 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

Phase Ii ◽

Induction Therapy ◽

Myeloid Leukemia ◽

Phase Ii Study ◽

Gemtuzumab Ozogamicin ◽

Download Full-text

A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation

Case Medical Research ◽

10.31525/ct1-nct04253314 ◽

2020 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

Russian Federation ◽

Induction Therapy ◽

Myeloid Leukemia ◽

Download Full-text